OverviewSuggest Edit

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the Company is developing two therapies targeting hematological malignancies: TG-1101 (ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes and TGR-1202, an orally available Phosphoinositide 3-kinase delta inhibitor.

TypePublic
Founded1993
HQNew York, US
Websitetgtherapeutics.com

Latest Updates

Employees (est.) (May 2020)153(+15%)
Revenue (FY, 2019)$152 K
Share Price (Sept 2020)$25.6
Cybersecurity ratingAMore

Key People/Management at TG Therapeutics

Michael S. Weiss

Michael S. Weiss

Executive Chairman, President and Chief Executive Officer
Sean A. Power

Sean A. Power

Chief Financial Officer
Adam Waldman

Adam Waldman

Chief Commercialization Officer
Owen A. O'Connor

Owen A. O'Connor

Chief Scientific Officer
Show more

TG Therapeutics Office Locations

TG Therapeutics has an office in New York
New York, US (HQ)
2 Gansevoort St 9th Floor
Show all (1)

TG Therapeutics Financials and Metrics

TG Therapeutics Revenue

TG Therapeutics's revenue was reported to be $152 k in FY, 2019
USD

Revenue (Q2, 2020)

38.0k

Net income (Q2, 2020)

(52.9m)

EBIT (Q2, 2020)

(50.8m)

Market capitalization (22-Sept-2020)

3.2b

Closing stock price (22-Sept-2020)

25.6

Cash (30-Jun-2020)

260.5m

EV

3.0b
TG Therapeutics's current market capitalization is $3.2 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

19.0k152.4k152.4k152.4k152.4k152.4k152.0k152.0k

Revenue growth, %

General and administrative expense

554.7k4.8m16.3m15.2m15.0m

R&D expense

327.3k21.0m13.7m40.1m47.7m69.2m102.5m159.4m154.2m
USDQ2, 2011

Financial Leverage

-8.5 x
Show all financial metrics

TG Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

TG Therapeutics Online and Social Media Presence

Embed Graph

TG Therapeutics News and Updates

TG Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at two upcoming virtual investor conferences. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, is scheduled to participate in fireside chats during the…

TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib

NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of preclinical data describing the unique immunomodulatory effects of umbralisib, the Company’s investigational oral once-daily dual inhibitor of PI3K-delta and CK1-epsilon, in Blood Ad…

TG Therapeutics to Present at the Raymond James 2020 Human Health Innovation Conference

Presentation scheduled for Thursday, June 18, 2020, at 3:40 PM ET Presentation scheduled for Thursday, June 18, 2020, at 3:40 PM ET

TG Therapeutics Announces Data Presentations at the 25th European Hematology Association (EHA) Annual Congress

NEW YORK, June 12, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the 25th European Hematology Association (EHA) annual congress including data from a Phase 1 study evaluating TG-1701, the Company’s once daily, selective, BTK inhibitor, as mono…

TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma

TG received guidance from the FDA allowing submission of a single NDA for Marginal Zone Lymphoma (MZL) and Follicular Lymphoma indications

TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Presentation scheduled for Thursday, January 16, 2020 at 8:00 AM PT Presentation scheduled for Thursday, January 16, 2020 at 8:00 AM PT
Show more

TG Therapeutics Blogs

TG Therapeutics to Present at the Jefferies 2020 Healthcare Conference

TG Therapeutics to Present at the Jefferies 2020 Healthcare Conference Content Import Tue, 06/02/2020 - 07:01 TG Therapeutics to Present at the Jefferies 2020 Healthcare Conference Jun 02, 2020 This release is a backfill from a News Wire General Releas…

TG Therapeutics Announces Final Results of the GENUINE Phase 3 Study Evaluating Ublituximab plus Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia at the 56th American Society of Clinical Oncology Annual Meeting

The addition of ublituximab to ibrutinib significantly improved PFS, ORR, CR rate, and increased rates of uMRD compared with ibrutinib monotherapy NEW YORK , May 29, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the final results from the GENUINE Phase 3 study

TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Meeting

TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Meeting Content Import Fri, 05/15/2020 - 07:01 TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Mee…

TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock Content Import Thu, 05/14/2020 - 22:08 TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock May 14, 2020 This release is a backfill from a News Wire Ge…

TG Therapeutics Announces Proposed Public Offering of Common Stock

NEW YORK , May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG Therapeutics”), today announced that it intends to offer and sell 6,000,000 shares of its common stock in

TG Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results

NEW YORK , May 11, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2020 and recent company developments. Michael S. Weiss , the Company's Executive Chairman and Chief Executive Officer, stated, “The first few
Show more

TG Therapeutics Frequently Asked Questions

  • When was TG Therapeutics founded?

    TG Therapeutics was founded in 1993.

  • Who are TG Therapeutics key executives?

    TG Therapeutics's key executives are Michael S. Weiss, Sean A. Power and Adam Waldman.

  • How many employees does TG Therapeutics have?

    TG Therapeutics has 153 employees.

  • What is TG Therapeutics revenue?

    Latest TG Therapeutics annual revenue is $152 k.

  • What is TG Therapeutics revenue per employee?

    Latest TG Therapeutics revenue per employee is $993 .

  • Who are TG Therapeutics competitors?

    Competitors of TG Therapeutics include Inovio Pharmaceuticals, Vertex Pharmaceuticals and JanOne.

  • Where is TG Therapeutics headquarters?

    TG Therapeutics headquarters is located at 2 Gansevoort St 9th Floor, New York.

  • Where are TG Therapeutics offices?

    TG Therapeutics has an office in New York.

  • How many offices does TG Therapeutics have?

    TG Therapeutics has 1 office.